Demo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase only
Predicts the obesity/GLP-1 franchise with the largest reported sales in Q4 2026. Resolves to the company with the highest obesity-drug revenue for the quarter. Source: company earnings reports.
This reminds me of a similar market last year. Same setup.
The volume on this market has been insane lately.
The market is pricing this wrong. Easy money here.
Just took some profits. Still holding a core position.
This is my largest position. Very confident.
The fundamentals support a higher probability here.
The fundamentals support a higher probability here.
The market is pricing this wrong. Easy money here.
Historical data suggests these markets tend to overcorrect. Buying the dip.
Been trading prediction markets for years. This is one of the clearest opportunities I've seen.
Great entry point at current prices. Loading up!
Great entry point at current prices. Loading up!
This needs more liquidity. Hard to get good fills.
GLP-1 obesity market leader end of 2026?
The recent news should move this significantly.